Number of fallers · people aged 60 years and older living in the community
1 finding from 1 review
no estimate extracted
3047 participants
Very low
Fall‐related injuries · people aged 60 years and older living in the community
1 finding from 1 review
no estimate extracted
67300 participants
Very low
Number of people sustaining one or more fall‐related fractures · people aged 60 years and older living in the community
1 finding from 1 review
no estimate extracted
24365 participants
Very low
Number of people who experience a fall that required hospital admission · people aged 60 years and older living in the community
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of fallers · community‐dwelling older adults ≥ 65 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people aged 60 years and older living in the community
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cost‐effectiveness · people aged 60 years and older living in the community
1 finding from 1 review
no estimate extracted
163683 participants
Very low
Fall‐related injuries · community‐dwelling older adults ≥ 65 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of people sustaining one or more fall‐related fractures · community‐dwelling older adults ≥ 65 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of people who experience a fall that required hospital admission · community‐dwelling older adults ≥ 65 years of age
1 finding from 1 review
no estimate extracted
4542 participants
Very low
Participants with at least some Side Effects · community‐dwelling older adults ≥ 65 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic analysis · community‐dwelling older adults ≥ 65 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Falls · people aged 60 years and older living in the community
1 finding from 1 review
no estimate extracted
1422 participants
Very low
Number of fallers · people aged 60 years and older living in the community
1 finding from 1 review
no estimate extracted
1422 participants
Very low
Cumulative incidence of herpes zoster, 3.1 years · healthy older adults aged ≥ 60 years
Live zoster vaccine probably leads to lower cumulative incidence of herpes zoster, 3.1 years compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ serious adverse events Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ serious adverse eventsClinical or… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects of any severity (systemic symptoms) · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any systemic symptomClinical… compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ potential immune‐mediated disease Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ potential immune‐mediated… compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ any local symptom Clinical criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any local symptomClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review
Dropouts ‐ did not receive second dose Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher dropouts ‐ did not receive second doseClinical or laboratory criteria compared with placebo (moderate certainty).
1 finding from 1 review